JM

Jagadeeswara Madineni Naidu

Director Director DIN 05171653
DIN 05171653 First appointment Apr 2012 Primary industry Research & Development
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 1 historical roles
Total affiliations 1 Since Apr 2012
Shareholding value β€’β€’β€’β€’ Premium profile

About Jagadeeswara Madineni Naidu

Data last updated:

Jagadeeswara Madineni Naidu was a Director at Caraka Clinical And Translational Sciences Private Limited (2012–2018). The company operates in Research & Development.

DIN 05171653
Primary Designation Director
Industry Research & Development
First Appointment 23 Apr 2012

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director23 Apr 20122012₹1.6 Lakh (FY 2024)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Caraka Clinical And Translational Sciences Private Limited
Premium access

Shareholding and investment profile for Jagadeeswara Madineni Naidu

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jagadeeswara Madineni Naidu

Jagadeeswara Madineni Naidu was first appointed on 23 Apr 2012 as Director at Caraka Clinical And Translational Sciences Private Limited.

Jagadeeswara Madineni Naidu held 1 earlier board appointment: Caraka Clinical And Translational Sciences Private Limited (Director, 23 Apr 2012 to 03 Oct 2018).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available